Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients

Mycoses

Volumn 54, Issue 6, 2011, Pages 523-530

  Park, Sun Hee ^a   Choi, Su Mi ^a   Lee, Dong Gun ^a   Choi, Jung Hyun ^a   Kim, Si Hyun ^a   Kwon, Jae Cheol ^a   Yoo, Jin Hong ^a   Kim, Hee Je ^b   Lee, Seok ^b   Eom, Ki Seong ^b   Min, Woo Sung ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Galactomannan; Invasive aspergillosis; Leukaemia; Neutropenia; Surrogate marker

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CILASTATIN PLUS IMIPENEM; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLUS FUMIGATUS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE DURATION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CLINICAL LABORATORY TECHNIQUES; FEMALE; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; LEUKEMIA; MALE; MANNANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SERUM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053996515     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.02009.x     Document Type: Article

References (32)

1. Slobbe L, Polinder S, Doorduijn JK et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008; 47: 1507-12.
2. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67: 1567-601.
3. Pagano L, Caira M, Candoni A et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95: 644-50.
4. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 2010; 50: 405-15.
5. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
6. Miceli MH, Maertens J, Buve K et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007; 110: 112-20.
7. Anaissie EJ. Trial design for mold-active agents: time to break the mold - aspergillosis in neutropenic adults. Clin Infect Dis 2007; 44: 1298-306.
8. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5: 609-22.
9. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-57.
10. Maertens J, Buve K, Theunissen K et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009; 115: 355-62.
11. Woods G, Miceli MH, Grazziutti ML, Zhao W, Barlogie B, Anaissie E. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110: 830-4.
12. Boutboul F, Alberti C, Leblanc T et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34: 939-43.
13. Cordonnier C, Botterel F, Ben Amor R et al. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect 2009; 15: 81-6.
14. Miceli MH, Grazziutti ML, Woods G et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46: 1412-22.
15. Marr KA. Aspergillus galactomannan index: a surrogate end point to assess outcome of therapy? Clin Infect Dis 2008; 46: 1423-5.
16. Asano-Mori Y, Kanda Y, Oshima K et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother 2008; 61: 411-6.
17. Cordonnier C, Botterel F, Ben Amor R et al. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect 2009; 15: 81-86.
18. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
19. Maertens J, Theunissen K, Lodewyck T, Lagrou K, Van Eldere J. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007; 50(Suppl. 1): 2-17.
20. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
21. Link H, Bohme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82(Suppl. 2): S105-17.
22. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112: 2309-12.
23. Kraemer HC, Periyakoil VS, Noda A. Kappa coefficients in medical research. Stat Med 2002; 21: 2109-29.
24. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-9.
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
26. Yoo JH, Choi SM, Lee DG et al. Prognostic factors influencing infection-related mortality in patients with acute leukemia in Korea. J Korean Med Sci 2005; 20: 31-35.
27. Park HY, Suh GY, Jeon K et al. Outcome and prognostic factors of patients with acute leukemia admitted to the intensive care unit for septic shock. Leuk Lymphoma 2008; 49: 1929-34.
28. Maertens J, Theunissen K, Verhoef G, Van Eldere J. False-positive Aspergillus galactomannan antigen test results. Clin Infect Dis 2004; 39: 289-90.
29. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917-20.
30. Tanriover MD, Ascioglu S, Altun B, Uzun O. Galactomannan on the stage: prospective evaluation of the applicability in routine practice and surveillance. Mycoses 2010; 53: 16-25.
31. Yoo JH, Choi JH, Choi SM et al. Application of nucleic acid sequence-based amplification for diagnosis of and monitoring the clinical course of invasive aspergillosis in patients with hematologic diseases. Clin Infect Dis 2005; 40: 392-8.
32. White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479-86.